NO2873664T3 - - Google Patents

Info

Publication number
NO2873664T3
NO2873664T3 NO13817593A NO13817593A NO2873664T3 NO 2873664 T3 NO2873664 T3 NO 2873664T3 NO 13817593 A NO13817593 A NO 13817593A NO 13817593 A NO13817593 A NO 13817593A NO 2873664 T3 NO2873664 T3 NO 2873664T3
Authority
NO
Norway
Application number
NO13817593A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2873664T3 publication Critical patent/NO2873664T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
NO13817593A 2012-07-12 2013-06-04 NO2873664T3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210240697.0A CN103539783A (zh) 2012-07-12 2012-07-12 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
PCT/CN2013/076717 WO2014008794A1 (zh) 2012-07-12 2013-06-04 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法

Publications (1)

Publication Number Publication Date
NO2873664T3 true NO2873664T3 (no) 2018-03-31

Family

ID=49915377

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13817593A NO2873664T3 (no) 2012-07-12 2013-06-04

Country Status (21)

Country Link
US (1) US9309226B2 (no)
EP (1) EP2873664B1 (no)
JP (1) JP6170146B2 (no)
KR (1) KR102078077B1 (no)
CN (2) CN103539783A (no)
AU (1) AU2013289789B2 (no)
BR (1) BR112015000045B1 (no)
CA (1) CA2876884C (no)
DK (1) DK2873664T3 (no)
ES (1) ES2656623T3 (no)
HK (1) HK1199027A1 (no)
HU (1) HUE037946T2 (no)
MX (1) MX349672B (no)
NO (1) NO2873664T3 (no)
PL (1) PL2873664T3 (no)
PT (1) PT2873664T (no)
RU (1) RU2631321C2 (no)
TW (1) TWI597277B (no)
UA (1) UA113658C2 (no)
WO (1) WO2014008794A1 (no)
ZA (1) ZA201500471B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105985408B (zh) * 2015-02-12 2020-06-26 正大天晴药业集团股份有限公司 一种卡非佐米的纯化方法
CA2986349A1 (en) 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
CN107405345A (zh) * 2016-01-27 2017-11-28 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物的制备方法
CA3011525C (en) * 2016-01-27 2023-12-05 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising quinoline derivative or salt thereof
CN112426424A (zh) * 2016-01-28 2021-03-02 江苏恒瑞医药股份有限公司 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
CN112645932B (zh) * 2016-03-22 2022-01-14 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用
TW201827050A (zh) 2017-01-22 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Egfr/her2抑制劑聯合嘧啶類抗代謝藥物的用途
WO2019029477A1 (zh) * 2017-08-07 2019-02-14 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法
CN109516976B (zh) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法
US11701349B2 (en) 2017-10-24 2023-07-18 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing quinoline derivative
CN110960529A (zh) * 2018-09-30 2020-04-07 江苏恒瑞医药股份有限公司 一种降低了毒性杂质含量的酪氨酸激酶抑制剂的原料药
TWI762825B (zh) 2018-10-22 2022-05-01 大陸商江蘇恒瑞醫藥股份有限公司 酪胺酸激酶抑制劑的一馬來酸鹽的晶型及其製備方法
CN111138414A (zh) * 2018-11-05 2020-05-12 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的晶型及其制备方法
TW202115027A (zh) * 2019-08-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 低雜質含量的酪胺酸激酶抑制劑
CN114674937A (zh) * 2020-12-24 2022-06-28 沈阳药科大学 一种马来酸长链脂肪酰胺中长链脂肪胺的测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
KR102078077B1 (ko) 2020-02-17
MX349672B (es) 2017-08-08
DK2873664T3 (en) 2018-01-08
ZA201500471B (en) 2016-10-26
WO2014008794A1 (zh) 2014-01-16
ES2656623T3 (es) 2018-02-27
US9309226B2 (en) 2016-04-12
TW201402563A (zh) 2014-01-16
EP2873664A1 (en) 2015-05-20
MX2014015623A (es) 2015-06-23
PL2873664T3 (pl) 2018-06-29
CN103974949A (zh) 2014-08-06
KR20150036336A (ko) 2015-04-07
US20150166511A1 (en) 2015-06-18
CA2876884A1 (en) 2014-01-16
PT2873664T (pt) 2018-01-24
CN103539783A (zh) 2014-01-29
AU2013289789A1 (en) 2015-01-22
CN103974949B (zh) 2015-11-25
RU2015103065A (ru) 2016-08-27
HK1199027A1 (zh) 2015-06-19
EP2873664B1 (en) 2017-11-01
HUE037946T2 (hu) 2018-09-28
BR112015000045A2 (pt) 2017-06-27
AU2013289789B2 (en) 2017-06-29
EP2873664A4 (en) 2015-12-30
UA113658C2 (xx) 2017-02-27
TWI597277B (zh) 2017-09-01
RU2631321C2 (ru) 2017-09-21
BR112015000045B1 (pt) 2021-10-26
JP6170146B2 (ja) 2017-07-26
CA2876884C (en) 2019-12-10
JP2015522042A (ja) 2015-08-03

Similar Documents

Publication Publication Date Title
BR112014017635A2 (no)
BR112014017614A2 (no)
BR112014017592A2 (no)
BR112014017625A2 (no)
BR112014030852A2 (no)
BR112014017659A2 (no)
BR112014019815A2 (no)
BR112014017646A2 (no)
AR092201A1 (no)
BR112014017607A2 (no)
BR112013027865A2 (no)
BR112014017634A2 (no)
BR112014017609A2 (no)
BR112014017673A2 (no)
NO2873664T3 (no)
BR112014017588A2 (no)
BR112014017647A2 (no)
BR112014013184A8 (no)
BR112014017618A2 (no)
BR112014017630A2 (no)
BR112014017652A2 (no)
BR112014017621A2 (no)
BR112014017756A2 (no)
BR112014017627A2 (no)
BR112014017623A2 (no)